Anavex Life Sciences Corp

NASDAQ AVXL

Data sourced from

and

Download Data

Anavex Life Sciences Corp Sales to Working Capital Ratio 3 year CAGR for the year ending September 30, 2023

Anavex Life Sciences Corp Sales to Working Capital Ratio 3 year CAGR is NA for the year ending September 30, 2023. The sales to working capital ratio measures the revenue generated by a company relative to its working capital. It is calculated by dividing the revenue by the difference between current assets and current liabilities. This ratio indicates the company's revenue generation efficiency based on its working capital. A higher sales to working capital ratio suggests better utilization of working capital to generate sales revenue. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.

Anavex Life Sciences Corp Sales to Working Capital Ratio for the year ending September 30, 2022 was 0.00, a 0.00% change year over year.
Anavex Life Sciences Corp Sales to Working Capital Ratio for the year ending September 30, 2021 was 0.00, a 0.00% change year over year.
Anavex Life Sciences Corp Sales to Working Capital Ratio for the year ending September 30, 2020 was 0.00, a 0.00% change year over year.
Anavex Life Sciences Corp Sales to Working Capital Ratio for the year ending September 30, 2019 was 0.00, a 0.00% change year over year.

NASDAQ: AVXL

Anavex Life Sciences Corp

CEO	Dr. Christopher U. Missling M.B.A., M.S., Ph.D.
IPO Date	Aug. 2, 2006
Location	United States
Headquarters	630 5th Avenue, New York, NY, United States, 10111
Employees	40
Sector	Healthcare
Industry	Biotechnology

Description

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.

Key trends